Julie Trautwein

TL;DR: A multistage microfluidic device that is capable of sorting rare circulating tumor cells (CTCs) that are either positive or negative for the surface antigen epithelial cell adhesion molecule (EpCAM) and could be a promising addition to current diagnostic tools used in the clinic is developed.

TL;DR: The procedure for isolating rare CTCs from blood samples by using tumor antigen–independent microfluidic CTC-iChip technology, which uses deterministic lateral displacement, inertial focusing and magnetophoresis to sort up to 107 cells/s.

TL;DR: Analysis of circulating tumor cells from prostate cancer patients reveals a mechanism that contributes to treatment failure, and a non-invasive method to spot resistance by sequencing RNA transcripts in single circulating tumor Cells (CTCs) is developed.

TL;DR: Mouse as well as human pancreatic CTCs exhibit a very high expression of stromal-derived extracellular matrix (ECM) proteins, including SPARC, whose knockdown in cancer cells suppresses cell migration and invasiveness, pointing to their contribution of microenvironmental signals for the spread of cancer to distant organs.

TL;DR: Microfluidic capture of circulating tumor cells (CTC) is used to measure AR signaling readouts before and after therapeutic interventions to help target treatments to patients most likely to respond to second-line therapies.